Amphiregulin as a Novel Resistance Factor for Amrubicin in Lung Cancer Cells

S. Tokunaga(Kobe University), Yoshihiro Nishimura(Kobe University)

Anticancer Research

May 7, 2017

10.21873/anticanres.11558

Cited by 8

Related Papers

Glucose metabolism‐targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor‐induced drug‐tolerant persisters

|Cancer Science|2017|37

Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer

|Molecules|2020|35

Phospholipase Cε plays a crucial role in neutrophilic inflammation accompanying acute lung injury through augmentation of CXC chemokine production from alveolar epithelial cells

|Respiratory Research|2019|14

<p>Caspase Recruitment Domain-Containing Protein 9 Expression is a Novel Prognostic Factor for Lung Adenocarcinoma</p>

|OncoTargets and Therapy|2020|4